Table 1 Clinical and demographic characteristics of SLE and HC groups

Case number

30

30

40

18

Age (years) ^a

33.9 ± 10.1

31.2 ± 4.5

35.9 ± 10.5

32.2 ± 10.3

Disease duration, yrs ^a

6.3 ± 5.6

5.7 ± 5.2

Gender (F/M)

29/1

30/0

35/5

16/2

SLEDAI ^a

18.9 ± 8.5

-

17.5 ± 4.8

GC dose (mg/d) ^a

27.9 ± 26.6

33.6 ± 36.6

Organ involvement (n,%)

Renal involvement

24,80%

31,77.50%

Hematologic

11,36.67%

15,37.50%

Neuropsychiatric

2,6.67%

3,7.50%

Musculoskeletal

12,40.00%

16,40.00%

Cutaneous

16,53.33%

18,45.00%

Gastrointestinal

2,6.67%

3,7.5%

Laboratory data

C3 (mg/dl) ^a

0.7 ± 0.3

0.7 ± 0.3

C4 (mg/dl) ^a

0.1 ± 0.05

0.1 ± 0.08

ESR (mm/h) ^a

40.6 ± 24.9

40.9 ± 32.7

CRP (mg/l) ^a

15.93 ± 35.7

7.6 ± 10.9

Cr (mg/dl) ^a

91.4 ± 98.2

109.9 ± 133.3

BUN (mg/dl) ^a

8.5 ± 5.4

10.1 ± 6.2

eGFR(m/min/1.73m²) ^a

112.6 ± 56.3

101.6 ± 58.3

Proteinuria (mg/24hr) ^a

2734.2 ± 4530.4

5174 ± 6144

Treatment (n,%)

Glucocorticoid

29, 96.7%

40, 100%

Cyclophosphamide

10, 33.3%

13, 32.5%

Hydroxychloroquine

19, 63.3%

28, 70%

Mycophenolate mofetil

7, 23.3%

10, 25%

Cyclosporin A

4, 13.3%

6, 15%

Tacrolimus

7, 23.3%

8, 20%